BLRX News and Press, BioLineRx Ltd. From 04/17/23

BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma PR Newswire - GENESIS trial achieved statistical significance (p<0.0...

2023-03-22 15:22:03 ET BioLineRx Ltd. (BLRX) Q4 2022 Earnings Conference Call March 22, 2023 10:00 ET Company Participants John Lacey - Investor Relations Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercia...

2023-03-22 07:11:23 ET biolinerx press release ( NASDAQ: BLRX ): FY GAAP EPS of -$0.03 beats by $0.34 . As of December 31, 2022, the Company had cash, cash equivalents, and short-term bank deposits of $51.1 million and anticipates this will be sufficient to fund o...

BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates PR Newswire - Announced FDA Acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in Stem Cell Mobilization with Prescription Drug User Fee Act (PDUFA) Target Action Date o...

2023-03-21 12:21:10 ET biolinerx ( NASDAQ: BLRX ) is scheduled to announce FY earnings results on Tuesday, March 21st, after market close. The consensus EPS Estimate is -$0.54 and the consensus Revenue Estimate is $0M. For further details see: biolinerx FY 2022 E...

BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease PR Newswire - Clinical trial part of long-term growth strategy for mo...

BioLineRx ( NASDAQ: BLRX ) has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer, effective January 4, 2023. Dr. Rachmilewitz brings over 15 years of clinical development industry experience to the Company, including overseeing clinical development programs in oncology, ...

BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer PR Newswire Experienced Drug Developer Brings Over 15 Years of Clinical Development Industry Knowledge across Multiple Therapeutic Areas and Modalities TEL AVIV, Israel , Jan. 4, 2023 ...

AGI-134, an intratumoral cancer vaccine candidate from BioLineRX ( NASDAQ: BLRX ), demonstrated safety and tolerability in a phase 1/2a trial . In the accelerated dose-escalation part of the study, there were no dose-related toxicities reported. In the dose expansio...

BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors PR Newswire Study Met Primary Endpoint for Safety and Tolerability First-in-Human, Single-Agent Study Demonstrated Immune Activity Across Multiple Bio...